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Stem cell-based therapies for repair and regeneration of different tissues are becoming more important in the
treatment of several diseases. Adult stem cells currently symbolize the most available source of cell progenitors
for tissue engineering and repair and can be harvested using minimally invasive procedures. Moreover, mes-
enchymal stem cells (MSCs), the most widely used stem cells in stem cell-based therapies, are multipotent
progenitors, with capability to differentiate into cartilage, bone, connective, muscle, and adipose tissue. So far,
bone marrow has been regarded as the main source of MSCs. To date, human adult adipose tissue may be the
best suitable alternative source of MSCs. Adipose stem cells (ASCs) can be largely extracted from subcuta-
neous human adult adipose tissue. A large number of studies show that adipose tissue contains a biologically
and clinically interesting heterogeneous cell population called stromal vascular fraction (SVF). The SVF may
be employed directly or cultured for selection and expansion of an adherent population, so called adipose-
derived stem cells (ASCs). In recent years, literature based on data related to SVF cells and ASCs has
augmented considerably: These studies have demonstrated the efficacy and safety of SVF cells and ASCs
in vivo in animal models. On the basis of these observations, in several countries, various clinical trials
involving SVF cells and ASCs have been permitted. This review aims at summarizing data regarding either
ASCs cellular biology or ASCs-based clinical trials and at discussing the possible future clinical translation of
ASCs and their potentiality in cell-based tissue engineering.
Introduction
In recent years, stem cells have been contemplated to bea novel option in clinical therapy regarding tissue for-
mation and regenerative medicine with the utilization of
biomaterial scaffolds and growth factors.
Stem cells can be defined as undifferentiated cells with a
capacity of self renewal and differentiation into multiple
lineages.1 In contrast to embryonic stem cells, stem cells
that arise from differentiated tissues are immuno-compatible
and are not subject to ethical challenges.2,3 Mesenchymal
stem cells (MSCs) isolated from adult tissues have proved,
so far, to be the most suitable for clinical applications. Bone
marrow is considered an important site for hematopoietic
stem cells and is, additionally, the main source of MSCs as a
part of its stromal fraction.4–7 MSCs serve as a small,
nonhematopoietic committed subpopulation of cells located
in the bone marrow, already reported by Friedenstein et al.8
These multipotent cells are easily isolated from bone mar-
row and can expand and differentiate into mesoderm-
derived lineages such as adipocytes, chondrocytes, osteo-
blasts, and myoblasts9–12 as well as into neuro-ectodermal-
derived lineages such as neurons.13 These observations gave
rise to the birth of MSC-based therapies: Clinical trial in-
vestigations using bone marrow-derived MSCs to treat de-
bilitating conditions such as osteogenesis imperfecta,14
myocardial infarction,15 and strokes16 have shown some
therapeutic promises. However, the clinical use of bone
marrow MSCs has raised several issues worthy of addres-
sing, including the procedure of bone marrow harvest with
related pain, side effects, and morbidity. To address these
problems, many researchers have investigated alternative
sources of MSCs and recently new sources have been dis-
covered in the following tissues: dental pulp,17,18 Wharton
jelly,19 amniotic fluid,20 and adipose tissue.21 Adipose tis-
sue, as well as bone marrow, originates from the mesen-
chyme and contains a supporting stroma that could be
readily available for isolation. Based on this observation,
studies have reported that adipose tissue may be an impor-
tant source of MSCs with far-reaching effects in various
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fields. MSCs may be largely isolated from adipose tissue
and in culture is able to display stable growth and prolif-
eration kinetics.22,23 Adipose stem cells (ASCs), as in bone
marrow MSCs, can differentiate in vitro into adipogenic,
osteogenic, chondrogenic, and myogenic cells when cul-
tured in specific lineage-inducing culture media24–27 and
into endothelial cells.28
In conclusion, the high abundance of adipose tissue
within the body, its high surgical accessibility, and the
demonstrated multi-potency of ASCs show adipose tissue as
a promising candidate for MSCs harvest and increase the
interest in its use in tissue repair, regenerative medicine, and
degenerative disease management. The aim of this review is
to summarize the body of literature and the data regarding
this topic.
Isolation, Amplification, and Advantages of MSCs
Derived from Adipose Tissue
As reported by the International Federation for Adipose
Therapeutics and Science (IFATS),29 ASCs seem to be ideal
in regenerative medicine applications for many reasons:
They can be harvested, handled, and increased in number in
a noninvasive, easy, and effective manner.
In the 1960s, Rodbell et al.30 were pioneers of the first
methods for ASCs isolation. Subsequently, this procedure
was modified by Zuk et al. in 200124 to allow stem cell
isolation from human adipose tissue specimens. There may
still be discrepancies regarding the results from laboratories
due to the differences in methods used. To overcome this
problem, Nicoletti et al. set a new standard protocol to
isolate ASCs from human adipose tissue using enzymatic
digestion31 (Fig. 1).
The great novelty of this protocol is that cells isolated
from adipose tissue were sorted by fluorescence-activated
cell sorting before plating (see Characterization of ASCs:
Immunophenotype and Immunomodulatory Properties):
This protocol guarantees a greater percentage of ASC purity
and viability. Moreover, this novel procedure has been
used by other groups to select a specific cell subpopulation
characterized by a specific immunophenotype (see Char-
acterization of ASCs: Immunophenotype and Immuno-
modulatory Properties).32,33 Nonetheless, it is still necessary
to establish one standardized protocol to isolate ASCs to be
used in clinical practice, providing more homogeneous and
consistent results in regenerative medicine. We may also
consider the important clinical implications of adipose tissue
auto grafting in patients affected by breast cancer. Using a
single standardized protocol would facilitate follow up and
permit comparisons between different institutions that op-
erate autologous transplantation of adipose tissue.
Characterization of ASCs: Immunophenotype
and Immunomodulatory Properties
In 2002, Zuk et al. reported that ASCs expressed multiple
clusters of differentiation (CD), similar to those observed in
bone marrow MSCs.21 It is worth mentioning that Gimble
et al. noted that adhesion substrates and culture time modify
the differentiation status of ASCs: In particular, after two
passages in culture, the ASCs show peculiar adhesion and
receptor molecules, surface enzymes, extracellular matrix
(ECM), and proteins that are correlated to the stromal cell
phenotype.34 Different groups performed direct comparisons
between human ASCs (hASCs) and bone marrow MSCs.
Data indicated by Zuk et al. reported that these two stem
cells were immunophenotypically 90% identical.21 More
recent papers have revised this previous statement, giving a
different panel of molecular identity.35 For instance, the
glycoprotein CD34 is evident on hASCs at the first passage
but is not present on bone marrow MSCs4 (Table 1). It is
worth mentioning that the presence of Stro-1 antigen, a
common bone marrow MSC-associated surface antigen, on
hASCs is a matter of debate.21,36 More recently, Sca-1
FIG. 1. Schematic repre-
sentation of adipose stem cells
(ASCs) isolation protocol de-
scribed byD’Andrea et al.85 in
2008. Adipose tissue obtained
by lipectomy or liposuction
was washed, mechanically
minced, and digested in col-
lagenase type I and dispase
solution. Digested tissue was
filtered and centrifuged. Ery-
throcytes were eliminated, and
the remaining cells were cul-
tured in Dulbecco’s modified
Eagle’s medium 10% fetal
bovine serum on plastic
dishes. After 3 days of culture,
adherent cells acquired a fi-
broblast-like or polygonal
shape and the cells were
characterized cytomethically
to establish the stemness de-
gree of this cell population.
Color images available online
at www.liebertpub.com/teb
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surface marker has been found in a cell subpopulation de-
rived from white adipose tissue enriched in stem cells.37,38
Pinpointing of the ASC surface immunophenotype has al-
lowed the possibility to improve or to refine the stem cell
population from the heterogeneous stromal vascular fraction
(SVF) cells. Scientific researchers have used immune-
magnetic beads or flow cytometry for positive and negative
selection of a cell subpopulation within the SVF. In par-
ticular, Miranville et al.39 and Suga et al.40 selected the
CD34+/CD31- cell subpopulation also expressing CD133
and ABCG2. This population exhibited characteristics of
endothelial progenitor cells. Moreover, Mitchell et al.41
characterized SVF behavior in vitro showing that at the
outset, stromal cell-associated markers (CD13, CD29,
CD44, CD63, CD73, CD90, CD166) had fewer SVF cells
increasing significantly in successive passages, whereas
stem cell markers (CD34 and ABCG2) subsequently de-
creased. Traktuev et al.42 detected the CD34+/CD31-/
CD144- cell subpopulation at peri-vascular level in adipose
tissue. This population showed smooth muscle (a-actin,
caldesmon, and calponin), pericytic (chondroitin sulfate
proteoglycan, CD140a, and CD140b), and mesenchymal
(CD10, CD13, and CD90) markers. Finally, De Francesco
et al.28 isolated a cell subpopulation characterized by posi-
tivity for CD29, CD34, CD44, CD90, CD105, and CD117
from SVF. This cell population differentiated both in vitro
and in vivo into endothelial cells, resulting in the formation
of capillary-like structures in a methylcellulose medium.
Interestingly, Sengenes et al.43 highlighted that the CD34-
positive SVF cell population included only the ASCs popu-
lation. Despite numerous studies that investigate the different
markers recommended to detect and isolate ASCs, there is
no unanimous consensus in using a specific combination of
CDs that may select MSCs from adipose tissue. The char-
acterization of biological behavior using other stemness
tests is fundamental. For example, the expression of tran-
scription factors such as OCT4, SOX2, and NANOG that are
involved in maintaining stem cells; the ability to proliferate;
self-renewal; and the differentiation potential are key factors
to be considered.
ASCs and bone marrow MSCs are immuno-privileged
and immune-tolerated in auto-graft in vivo. Several studies
have indicated that both ASCs and bone marrow MSCs
inhibit peripheral blood mononuclear cell proliferation,44,45
and ASCs show a higher level of secretion of cytokines with
potent immunomodulatory effects such as interleukin-12
(IL-12), tumor necrosis factor-alpha (TNF-a), and interfer-
on-gamma (IFN-g).46 These data suggest that ASCs, as well
as bone marrow MSCs, may be considered in allogenic
regulation47 and may be used to reduce graft-versus-host
diseases as reported by Fang et al.48
ASCs In Vitro Cell Potency
The multi-potency of ASCs, such as bone marrow MSCs,
plays an important role in mesodermal defect repair and
disease management. In particular, both ASCs and bone
marrow MSCs have demonstrated the ability to differenti-
ate into adipogenic,49,50 osteogenic,51,52 chondrogenic,53,54
endothelial cells,55,56 and the myogenic57,58 lineage. Note-
worthy, ASCs and bone marrow MSCs have also demon-
strated their competence to differentiate into other tissues
such as neuron-like cells59,60 and epithelial cells.61,62
Adipogenic lineage
In reconstructive plastic surgery, adipose tissue is fre-
quently a key factor in tissue loss or defect.63 In recent years,
fat grafting may not only depend on transplantation of adult
adipocytes but may also rely on transplantation of the ASC
fraction.64,65 Growth hormone, glucocorticoids, insulin, and
prostaglandins are stimulatory for ASCs in adipocyte differ-
entiation in the initial and final stages. Consequently, the
adipogenic media are usually supplemented with the second
messenger cyclic adenosine monophosphate (cAMP) inducer
3-isobutyl-1-methyl-xantine (IBMX), and dexamethasone,
human recombinant insulin, and indomethacin. These sub-
stances activate gene expression involved in adipogenic dif-
ferentiation and inhibit the expression of those genes that aid
in maintaining stemness and/or in the differentiation pro-
cess of other tissues. The adipogenic conditions that have an
impact on ASCs are necessary to acquire the morphology
specific to lipid-laden cells evidencing intracellular lipid
Table 1. Cluster of Differentiation
CD ASCs BM-MSCs
CD9 ++ +
CD10 ++ –
CD11a — +
CD11b — +
CD11c — +
CD13 ++ ++
CD14 — —
CD16 — +
CD18 — +
CD29 ++ ++
CD31 – +
CD34 + -
CD44 ++ ++
CD45 — -
CD49b – ++
CD49d – ++
CD49e ++ ++
CD50 — +
CD51 ++ ++
CD54 – +
CD55 ++ ++
CD56 — +
CD59 ++ ++
CD61 – –
CD62e – +
CD63 – –
CD71 – +
CD73 + ++
CD90 ++ ++
CD104 — –
CD105 ++ ++
CD106 – +
CD117 - ++
CD133 – ++
CD140a – +
CD146 – ++
CD166 + +
++ , >70%; +, 30–70%, – , 10–30%; -, 2–10%; —, <2%; ASC,
adipose stem cell; BM, bone marrow; CD, clusters of differenti-
ation; MSC, mesenchymal stem cell.
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droplets, which exhibit adipocyte marker expression such as
adiponectin and peroxisome proliferator-activated receptor
gamma (PPARc) even after 24 h (Fig. 2).
The production in vitro of adipose tissue is frequently
required in reconstructive and cosmetic surgery. The ca-
pacity of ASC to differentiate into mature adipocytes is
clearly evident in the exposure medium containing steroids,
a cAMP inducer, and fatty acids. The differentiation of
ASCs into adipocytes is unquestionable, and the discovery
of ASC as a regenerating source of adipocytes for fat
grafting is of great interest. For this purpose, many clinical
trials are set up with the aim of improving the results of fat
grafting for contour deformities or breast augmentation.
Interestingly, fat grafting is already largely involved in the
practical application of ASC, a procedure with a positive
clinical response.
Osteogenic lineage
In clinical practice, differentiation of ASC into osteoblasts
might be useful in repair and regeneration of fractures, and it
may assist bone grafting of join fusions.32,66 In 2003, Lee
et al. reported early demonstrations of in vivo bone recon-
struction after in vitro differentiation of ASCs toward the
osteoblastic lineage.67 In 2004, Cowan et al. showed that
ASCs, implanted onto apatite-coated scaffolds, were able to
heal critical-sized mouse calvarias defects.68 There is agree-
ment in the scientific community regarding the requirement
of dexamethasone and 1,25-dihydroxyvitamin D3 for in vitro
osteogenesis induction.21,27 Ascorbic acid addition is also
important, because this coenzyme works as a co-factor in the
hydroxylation of lysine and proline residues in collagen, ac-
celerating the synthesis of noncollagenous bone ECM pro-
teins. Moreover, b-glycerophosphate is necessary to calcify
and mineralize bone ECM (Fig. 2).
It is also important to generate bone to repair large bone
defects, in a clinical context. Traditionally, no vascularized
bone grafts may be retained adequate to repair bone defects
that are lesser than 6 cm, while vascularized bone grafts are
required to heal bigger areas. However, there is evidence
that ASCs differentiation toward the osteogenic lineage is
more complex than the adipogenic differentiation. Staining
for calcified ECM components such as Alizarin Red may be
a simple procedure. The markers commonly assessed to
demonstrate osteogenic differentiation are RUNX2, osteo-
calcin, osteopontin, type I collagen, and ALP. There are few
clinical trials regarding osteogenesis using ASCs. Bone
differentiation from ASCs is clearly possible, but develop-
ing clinically relevant volumes and length of bone in vitro
may remain an arduous task.
Chondrogenic lineage
ASCs could be used to treat traumas or arthritis in joints
and may be useful in joint reconstruction. ASCs have been
employed in rabbits for the repair of osteochondral de-
fects.69 Chondrogenic differentiation is induced in vitro by
insulin, transforming growth factor-beta 1 (TGF-b1), and
ascorbat eaddition without dexamethasone to the medium.
Enhanced expression of cartilage ECM proteins takes place
when a three-dimensional (3D) culture technique is used to
suspend ASCs.70 When cells grow as a monolayer, the
chondrogenic markers of differentiation are seen; however,
in reduced concentration and cellular differentiation, they
appear incomplete71 (Fig. 2).
ASCs are expected to positively generate cartilage for
clinical use in the treatment of joint degenerative diseases. The
use of cartilage regeneration instead of joint replacement may
be an alternative treatment with socioeconomic advantages. A
simple procedure used to demonstrate ASCs differentiation
into a chondrogenic lineage is staining for increased expres-
sion of proteoglycans using Alcian Blue or Safranin-O. Genes
frequently used for chondrogenic differentiation include type I
collagen, type II collagen, cartilage oligomeric matrix protein,
FIG. 2. Schematic representation
of ASCs proliferation and differ-
entiation potency. Color images
available online at www
.liebertpub.com/teb
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and aggrecan core protein. Considering the little evidence, to
date of structural improvement in the cartilage of the joint, one
may deduce that the symptomatic benefits observed in these
trials are linked to the anti-inflammatory properties of ASCs
rather than to the condrogenic differentiation. There is poor
evidence of cartilage reconstruction by ASC; therefore, new
protocols are required to obtain results.
Endothelial differentiation
The ability of ASCs in supporting angiogenesis is a matter
of debate, most likely because the cell population isolated by
the different scientific groups is not homogeneous and the
percentage of different cell precursors may undergo slight
alterations in the different laboratories. The first studies on
ASCs differentiation came to the conclusion that endothelial
cells were the most represented cell type in the SVF, as in-
dicated by the presentation of endothelial cell-specific
markers such as CD31, CD44, CD54, Flk1, and VEGF. In our
opinion, CD34+/CD90+ ASC sub-population is the best can-
didate for endothelial differentiation. There is good evidence,
in fact, that this sub-population produces both anti-apoptotic
and angiogenic factors, including vascular endothelial growth
factor (VEGF), hematopoietic growth factor (HGF), and
TGF-b.28 Since VEGF is necessary to promote endothelial
differentiation, we found, consistent with these molecular
data, that CD34+/CD90+ cells differentiated into endothelial
capillary-like structures. Other authors used an in vivo nude
mouse model of hind limb ischemia and demonstrated that
ASCs injection markedly improved limb perfusion, which
was coherent with an increase in blood flow and capillary
density in the limb39,72 (Fig. 2).
Myogenic lineage
Smooth and skeletal muscle cells have generally been re-
produced by differentiating the ASC in complete media with
5% horse serum, and glucocorticoid such as hydrocortisone
and/or dexamethasone. When cells are cultured under these
conditions, they appear to merge and form multi-nucleated
myotubes, generating protein markers for myocytes. ASCs,
cultured as mentioned earlier, express mRNAs encoding
myogenic proteins, including the transcriptional regulators
MyoD and myogenin as well as structural proteins such as
myosin heavy chain.73 The capacity of ASCs to differentiate
into muscle was recently demonstrated both in vitro and
in vivo.74 Two mechanisms are fundamental for muscle re-
generation from ASC, as a result of the de novo formation of
muscle-specific cells from ASCs and/or the change in gene
expression after direct fusion of ASCs with host cells (Fig. 2).
The myogenic potential of ASCs may be harvested in the
treatment of Duchenne muscular dystrophy (DMD). In vivo
murine studies have demonstrated that dystrophin expression
may be restored over the long term, and in vitro studies have
shown that ASCs can fuse with DMD myoblasts to re-
establish dystrophin expression. This symbolizes a promis-
ing challenge in the use of stem cell therapy for muscular
degenerative diseases.
Cryopreservation of ASCs
The possibility of MSC cryopreservation may have a po-
tential clinical use. This procedure is not normal routine
clinical practice, but major improvements have been made in
the cryopreservation of cells and tissues.75 However, hema-
topoietic stem cells have been largely cryopreserved and
subsequently employed with success for transplantation.76 It
is fundamental to minimize destruction of the stem cells
during the cooling and thawing processes. Therefore, opti-
mization of cryopreservation protocols aimed at the mainte-
nance of stem cell quality is a key factor in their banking.
Dimethyl sulfoxide (DMSO) is commonly used as a cryo-
preservant for cells, but it is widely known to be toxic at room
temperature. Trehalose is a nontoxic disaccharide of glucose
that may stabilize and preserve cells and cellular structures
during the freezing procedure. In particular, cryopreservation
of adipose tissue has been studied extensively,77 and some
authors have demonstrated both in vivo and in vitro that
trehalose adequately protects human fat grafts.78,79 We based
our previous study on these indications80, and we observed
the ability of ASCs to be cryopreserved using a solution of
4% DMSO and 6% trehalose plus 90% fetal bovine serum
(FBS). This method of cryopreservation showed successful
preservation of the ASCs after 1 year. According to De Rosa
and colleagues, trehalose adequately protects proteins and
membranes and preserves the latter even during dehydration.
Due to its stabilizing effect, trehalose has recently been used
in various biomedical,81 cosmetic, and pharmaceutical ap-
plications82, which also include solutions for vaccines and
organs in surgical transplant.83 A cryopreservation method
using trehalose as a cryoprotective agent is recommended for
a long-term preservation of ASCs compared with simple
cryopreservation or with the method of DMSO cryopreser-
vation alone. Trehalose is a white, odorless powder with a
45% relative sweetness of sucrose. Trehalose is a bisacetal,
nonreducing homodisaccharide with two linked glucose units.
Trehalose is an important bioprotectant thanks to the exis-
tence of a number of polymorphs. Furthermore, it is able to
transit between crystalline form and another without losing its
structural integrity. It may prevent the inactivation and ag-
gregation of proteins at lower temperatures and may stabilize
cell membrane by delaying the initial transformation from
liquid crystal to gel state. Trehalose may also increase cyto-
plasmic viscosity and therefore may reduce the possibility of
intracellular ice crystal formation that is often fatal to cells.
Elucidations on the ‘‘exceptional’’ bioprotective properties of
trehalose have been extensively and sufficiently reported by
Jain and Roy,84 which may be summarized as follows: (i) The
vitrification theory that hypothesizes that trehalose forms a
glassy matrix acting as a cocoon that physically shields the
protein or even the cells from abiotic stress; (ii) the prefer-
ential exclusion theory that suggests that there is no direct
interaction between trehalose and protein; and (iii) the water
replacement theory that proposes that the substitution of
water molecules by trehalose-forming hydrogen bonds
maintains the 3D structure and stabilizes biomolecules. The
effects of trehalose are most likely due to the combination of
these theories.
hASCs Used for Adipose Tissue Engineering
D’Andrea et al.85 performed, for the first time, a long-term
culture of sorted hASCs in Dulbecco’s modified Eagle’s
medium supplemented with 20% FBS for 4 months. These
cells formed aggregates at confluence, resulting in an ECM
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enriched with collagen fibers. Allowing these newly formed
nodules to grow, they formed a layer of univacuolar adipo-
cytes. Histological analyses of these structures showed that
adipose cells surround a central area of fibrous connective
tissue that is clearly positive for the connective/adipose
markers that are type I collagen, fibronectin, adiponectin, and
PPARg as well as for endothelial markers such as VEGF,
CD31, CD44, and CD54. This intriguing model of synergic
differentiation is of great importance in clinical practice,
since the co-differentiation of blood vessels is necessary to
build new healthy tissue in regenerative therapies.
The importance of ECM is well acquainted not only for
its chemical properties but also for its mechanical and physi-
cal properties that influence cell behavior. Investigators aim
at combining what they know about the tissue-specific
characteristics of ECM and how it alters with age and dis-
eases with materials science to discover new constructs to be
incorporated into the host system to restore tissue function.
Tissue-specific scaffolds and signaling systems are funda-
mental to make stem cells differentiate into the required
cells and for effective use in constructing 3D tissues. Adi-
pose tissue engineering may be a promising and adequate
solution to these problems with the use of hASCs, implanted
on 3D biomaterials: a tissue-engineered substitute that pro-
motes large-volume regeneration of the subcutaneous adi-
pose tissue layer.
In summary, when hASCs are seeded on scaffolds for
adipose tissue generation, various crucial factors need to be
considered: the chemical composition, the mechanical sta-
bility, and the 3D architecture of the carrier. In vivo con-
struct efficiency is likely to depend on the efficacy of the
inoculation in vitro of hASCs into the scaffold and on the
structure and chemical type of polymer utilized. In fact,
when hASCs differentiate into adipocytes, they gain a sig-
nificant volume; hence, a structure that is not growth im-
peding and permits stem cell differentiation is necessary.
Moreover, the biomaterial should maintain the stability and
the general morphology until replaced by adipose tissue, as
well as allowing biodegradation after growth achievement.
Besides, as previously mentioned, the matrix of the ideal
carrier should favor the interplay between angiogenesis and
adipogenesis, minimizing cellular ischemia.
Micronized acellular dermal matrix
(micronized Alloderm)86
Micronized acellular derma matrix is a material that may
be injected. It is versatile due to its intermediate-length
implant and many applications. Studies have shown that
Alloderm is an ideal scaffold for skin and oral mucosa in
tissue engineering. Moreover, Alloderm is able to coordi-
nate the arrangement of seeded keratinocytes and cultured
keratinocyte sheets into a 3D epidermal structure with
multiple layers and to recreate the original rete ridges at the
interface of the dermis.87 Yoo and Lim have experienced a
hASC-Alloderm complex that, after 2 months in vivo, pre-
sented many signet-ring cells, large capillaries, and differ-
entiated adipocytes that contained many lipid droplets. This
injectable-engineered adipose tissue can be useful to aug-
ment soft tissue. As for other injectable scaffolds, the area of
soft tissue that can be increased is limited; clinical trials are
needed to evaluate how much lost tissue can be regenerated.
Moreover, similar scaffold materials, such as acellular
dermis as well as small intestinal submucosa, amniotic
membrane tissue, cadaveric fascia, and the bladder acellular
matrix graft, on implantation, evoke a host-tissue response
that originates from angiogenesis and aids tissue deposition,
leading to restoration and repair.
Silk fibroin 3D scaffold
Silk-based biomaterial may prove beneficial in adipose
tissue engineering applications due to its absence of bio
burdens, low immunogenicity, slow degradation rate, plas-
ticity during processing, and remarkable mechanical prop-
erties; they have been shown to offer exceptional benefit in
producing functional tissue replacement for mesenchymal
tissues, such as ligament, cartilage, and bone.88 Mauney uti-
lized ASCs seeded on a 3D porous silk-based fibroin scaffold
for an in vivo study. After 4 weeks, a noteworthy increase in
the frequency of lipid accumulating cells was noted in the
silk fibroin scaffold, demonstrating that silk-based bioma-
terials also endorse in vivo adipogenesis. Altman et al. also
reported that hASCs seeded on a silk fibroin-chitosan scaf-
fold improved wound healing and displayed differentiation
into epithelial, endothelial, and fibrovascular components of
restored tissue.89
In conclusion, silk may be considered beneficial for tissue
engineering applications thanks to its low immunogenicity,
slow degradation, and strong mechanical characteristics.
Notwithstanding these favorable features, the lack of po-
tential in long-term in vivo soft tissues engineering appli-
cations may be a current limitation.
Polyglycolic acid and poly(lactic-co-glycolic acid)
Cho et al.90 engineered a dome-shaped mechanical sup-
port, constructed by reinforcing poly(glycolic acid) fiber-
based matrices with poly(l-lactic acid), seeded with hASCs,
and implanted into subcutaneous pockets of athymic mice.
Regeneration of adipose tissue in the construct was observed
at 6 weeks after implantation. Kang et al.91 used hASCs
seeded on polyglycolic acid (PGA) and cultured in adipo-
genic medium for 2 weeks before their implantation in
immune-deficient mice. The implants had developed new
adipose tissue and had maintained their natural dimensions
and shape, and novel blood vessels were observed in the newly
formed adipose tissue. Injectable poly(lactic-co-glycolic acid)
(PLGA) spheres with hASCs were employed as a noninva-
sive soft-tissue filler in a previous study.92 PLGA has aroused
considerable interest in clinical applications considering its
biocompatibility; its biodegradation rate; its approval for
clinical use in humans by the U.S. Food and Drug Admin-
istration (FDA); and its ability to modify surface properties
to provide better interaction cells/biomaterial. PLGA is a
linear copolymer that may have different preparation ratios
between lactic acid (LA) and glycolic acid (GA). Different
forms of PLGA may be acquired based on the ratio of the
constituent monomers used for polymerization. PLGA may
be dissolved in various solvents, such as chlorinated sol-
vents, acetone, or ethyl acetate. Moreover, it may be pro-
cessed into any size and shape, and may be encapsulated in
different-sized biomolecules. The physical properties of PLGA
seem to rely on various factors, including the initial molecu-
lar weight of the monomers, the LA:GA ratio, the exposure
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time to water, and the storage temperature. These key
characteristics enable an accessible use of PLGA biomate-
rials in clinical practice without provoking adverse effects in
patients.
Similarly, PGA has been widely used in tissue engi-
neering because of its chemical and mechanical properties.
PGA has hydrolytically labile ester bonds and is degraded
by nonenzymatic hydrolysis. The degradation is nontoxic
and is eliminated from the body as carbon dioxide and
water. Since this polymer is thermoplastic, it is readily
manufactured according to the different tissue specifica-
tions. However, PGA may provoke inflammation in the
transplantation site due to the lymphocyte homing.
Collagen sponge
Collagen, one of the most common biodegradable carri-
ers, is commonly used in tissue engineering due to the po-
rous matrix property, which supports cellular growth and
new matrix synthesis.93 Primarily, collagen biomaterials
presented nonhomogeneous structures with differences in
pore size94 that did not lead to cellular implant and growth;
progress in the manufacture of collagen matrix has resulted
in a regular architecture of the scaffold.95 In vivo the con-
struct collagen/hASCs displays a significant neovascular-
ization and adipocyte differentiation.96,97
Collagenous microbeads are a favorable scaffold for
ASC, eliciting ex vivo proliferation and differentiation in
small injectable particles.98 Studies have shown that adipose
tissues engineered with hASCs and type I collagen scaffolds
may be used in vivo as a substitute to the damaged tissue. In
fact, a recent study has provided evidence that hASCs can
attach, grow, and proliferate on the collagen I scaffold be-
cause they are compatible at cellular level and considered an
adequate vehicle for adipose tissue engineering and for
production of loose connective tissue.99
There has been widespread use of collagen for soft tissue
engineering. It offers, as a native tissue, biocompatibility,
biodegradability, and weak antigenicity and is accessible in
different forms as in 3D gels, fibers, scaffolds or sponges, and
microbeads. Studies have demonstrated that type I collagen is
highly compatible with living organisms and is largely used as
a scaffold for adipose tissue engineering considering that it is
themain fiber of the extra-cellularmatrix in connective tissues.
Fibrin gel
Fibrin in the blood has a fundamental role in hemostatis
with access via autologous plasma found in glue form or as
engineered microbeads. This natural biomaterial is a ver-
satile polymer and may be effective in wound healing.100
For this reason, fibrin gel has strong neovascularization and
tissue regeneration properties and it is used in a number of
applications in tissue engineering.101,102 hASCs embedded
in a 3D fibrin gel have the ability to modulate vasculariza-
tion of a healing wound.103 However, the adipogenic char-
acteristics of fibrin have not yet been tested.
Hyaluronic acid scaffold
Hyaluronic acid (HA) is a novel material used in tissue
engineering; it is available in the extra-cellular matrix of
several tissues, and it is assumed to support differentiation
stimulating the tissue repair.104,105 HA pore varied from 50
to 340mm. Evidence has shown that sponge type prevails
over other compositions with regards to weight, homoge-
neous distribution, and differentiated adipose tissue rate. In
3 to 8 weeks,106 the construct HA/hASCs led to the for-
mation of adipose tissue, fundamental for its resistance to
swelling and for the diameter of the interconnected pores
(120 mm). Hemmrich et al. in in vivo trials evaluated new
sponge architecture with pores of 400mm diameter that
yielded more satisfying results in terms of vascularization,
cell diffusion, and proliferation than collagen sponge with a
65 and 100 mm pore size. In vivo studies have demonstrated
the presence of an extensive formation of newly formed
vessels in all sponge depths after 12 weeks.107 However, the
new tissue was not totally formed by mature adipocytes. A
possible explanation is that the 400mm pore size is too big
to give the key stimuli of contact inhibition that let the cells
go through differentiation.108 A probable solution is to
synthesize a structure with a variable pore size between 100
and 400mm and to increase the number of seeded ASCs.
Although hyaluronan 3D scaffolds may be considered an
adequate 3D carrier for the culture and in vitro differentia-
tion of human adipocyte precursor cells, so far they have not
been particularly successful in adipose outcomes.
Adipose tissue as a scaffold: cell-assisted lipotransfer
In 2006, Matsumoto et al.109 developed a new method for
adipose tissue transplantation, called cell-assisted lipo-
transfer (CAL). In CAL, 50% of the aspirated fat volume is
prepared to be isolated in the SVF-containing hASCs.
During the isolation process, the remaining amount of the
aspirated fat will be used for grafting. Freshly isolated
SVFs, containing hASCs, blood cells (WBCs and RBCs),
pericytes, vascular endothelial cells, and other cells, adhere
to the aspirated fat that serves as a living scaffold before
transplantation. The authors transplanted fat portion without
hASCs (non-CAL) or CAL portion in SCID mice. Four
weeks later, they compared the amount of fat tissue in CAL
and non-CAL samples and noticed that CAL fat had a higher
survival rate than non-CAL fat and microvasculature was
more evidently seen in CAL fat. Two years later, Yoshimura
et al.110 applied this novel strategy for facial lipoatrophy and
for breast augmentation with excellent results. In the CAL
strategy, autologous hASCs are adopted to promote angio-
genesis, as well as to ameliorate the survival rate of grafts,
and to diminish postoperative atrophy.
hASCs Used to Build Other Tissues Different
from Adipose Tissue
Using this attractive cell population, recent studies have
explored the safety and efficacy of implanted/administrated
hASCs in various animal models. Furthermore, clinical
trials using hASCs have been initiated in some medical
subspecialties.
Tissue engineering for organ reconstruction is exten-
sively required in injuries and medical conditions but is
mostly considered beneficial in the treatment of deep burns
in response to its use of living substitutes to permanently
replace the epithelia. The technique of skin tissue engi-
neering has been the subject of various studies.111,112
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Bi-layered skin substitutes, including the epidermis and
the dermis, have become fundamental in developing the
dermal matrices over recent years together with the au-
tologous fibroblasts that aid in the repair mechanism of
burn wound healing.113 Trottier et al.114 defined the
mechanism of producing novel human skin substitutes
starting from keratinocytes and hASCs in vitro without
the support of exogenous or synthetic scaffolds. These
substitutes showed similar characteristics on a histologi-
cal and immunohistological level as the dermal fibroblast
substitutes.
Recent progress in bone tissue engineering has focused
on developing biological substitutes to regenerate, pre-
serve, or ameliorate tissue function. One of the primary
targets of clinical therapeutic strategies is the regeneration
of bone to repair large bone defects caused by traumatic
events, infection, tumor enucleation, and skeletal defor-
mities. Autologous grafts represent the ideal graft bone
substitutes. An alternative approach involves the use of
allogenic bone grafts taken from corpses or living donors.
The limited success of auto and allografts has stimulated
the investigation of a wide variety of biomaterials for
scaffold use in in vitro tissue engineering. Many types of
materials have been used to confirm the availability of
ASCs for bone tissue engineering, including ceramics,115
titanium scaffold,116 natural and synthetic polymers117,118
with variable porosity, roughness, and methods of fabri-
cation. Differences in currently applied techniques make
studies complicated to compare and the lack of guidelines
to control safety in the use of the different materials in-
volved in bone scaffolds may be a matter of concern.
Prospective randomized clinical trials are needed to
demonstrate clinical outcomes of the ASCs therapies.
Cartilage tissue engineering has been increasingly ex-
plored in the past few years. The complexity and the
specificity of cartilage reside in its aneural, avascular, and
alymphatic nature. In this context, cartilage regeneration
represents one of the most difficult dares in tissue engi-
neering and clinical applications. Novel scaffolds, which
facilitate the differentiation of ASCs into cartilaginous
phenotype, play an important role. A broad range of
natural polymers have been studied as scaffolds119,120
together with synthetic materials such as PLGA and
others,121,122 as well as chitosan-HA.123 In this scenario,
it is important to mimic the cartilage tissue environment
(by tridimensional application) and to use prochondro-
genic factors in the design of biomaterials such as HA and
chondroitin sulfate.
ASCs have been recognized as a promising tool to
address the cure of liver cirrhosis. Interestingly, Ruiz
et al.,124 confirming and extending the previous report,125
documented that hASCs were able to develop the bio-
chemical features of mature hepatocytes after induction
using a successful combination of HGF and Oncostatin M
induction in vitro. The in vivo study demonstrates that
hASCs and ASC-derived hepatic cells are closely em-
bodied in the liver and form large cords of parenchymal
tissue. These data implicate the permissive role of the
adult liver environment in hASC hepatogenesis.
Acute and chronic ischemic heart diseases are among
the main causes of mortality worldwide. Conventional
management generally does not replace cardiomyocyte
mass loss or myocardial fibrotic tissue. hASCs extempo-
raneously differentiate into cardiomyocytes in vitro, ex-
press the cardiac-specific markers troponin-I and myosin
light chain 2,126,127 and spontaneously and rhythmically
contract.37 However, the in vivo differentiation of hASCs
into cardiomyocytes is still considered a controversial issue.
The myogenic properties of hASCs can be exploited in
the treatment of DMD, an inherited genetic disorder
progressively leading to skeletal muscle degeneration. In
vivo murine studies were carried out in vivo to show that
hASCs implanted into dystrophin-deficient immunocom-
petent mice restored dystrophin expression in the muscle
injection site and in the surrounding muscles over the
long term.128 The reconstruction of skeletal muscle tissue
in vitro has been widely endeavored, and the idea of
engineering new fibres has become an attractive option
since the introduction of ablation procedures by surgery
or from major traumas.129 Besides, numerous scaffold
materials have been studied for auto-transplantation for
both in vitro and/or in vivo growth and differentiation. For
example, HA scaffolds have been employed as a cell-
carrier material and play an important role in cellular
behavior. In a recent study, the possible use of a modified
crosslinked HA scaffold on different subpopulation of
hASCs has been evaluated. The authors pinpointed a
subpopulation of CD34-positive cells also expressing
NG2, a perycite marker, according to Traktuev et al.42
The CD34+/NG2+ population, seeded onto this new
scaffold, leads to differentiation into skeletal muscle tis-
sue. The acquired muscle tissue was made up of an or-
ganization of myofibers showing peripherally located
nuclei of human origin, confirmed as positive (for I Class
HLA and MyoD expression.130
Conclusion
The potential use of ASCs in plastic surgery is unlimited
and a wide range of treatments and reconstructions are
necessary to be used in different fields ranging from on-
cology to aesthetics, to adequately address individual patient
needs. The use of adipose tissue-derived stem cells as a
therapeutic tool has grown substantially in the past decade
and has stimulated the growth of a new research field and
industry worldwide. Adipose-derived cells may be used in a
wide range of clinical disorders depending on the target
tissue or on the underlying condition (immunological or
ischemic). Nevertheless, there are still some unclear aspects
in the basic knowledge of ASCs biology and the clinical
applications29 regarding the identity of adipose tissue-de-
rived cell populations and their use in clinical practice. The
IFATS and International Society for Cellular Therapy
(ISCT) provide initial guidance to academia and industries
regarding the properties of adipose tissue-derived cells. The
guidelines for the characterization of hASCs regard the vi-
ability, standard immunophenotype, proliferation, and dif-
ferentiation. These features facilitate the development of
further endpoints and accelerate safe and effective delivery
of hASC-based tools to the medical community and the pa-
tients. ASCs have prominent and strong involvements in tis-
sue regeneration due to their high cell yield in adipose tissue,
their ability to differentiate into multiple lineages, to secrete
various cytokines and thanks to their immunomodulatory
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effects. A wide number of clinical trials using ASCs have
already been performed, and many of them are ongoing. ASCs
are a promising cell source for regenerative medicine, and
further research is necessitated to guarantee the safety of
ASCs and the effectiveness of tissue engineering using
ASCs. For this reason, it is important to define success rate
of the engineered tissue before application; determine the
biomechanical properties of the engineered tissue; develop
guidelines to establish the biomechanical requirements of
the tissue to be replaced; design and characterize the bio-
mechanical and biophysical properties of the scaffold to be
used; specify the microenvironment of the implant construct;
and identify the potential risks for oncological patients.
These days, it is possible to employ stem cells acquired
from adipose tissue or bone marrow in various ways. For
example, they can be exploited for culture and expansion in
adequate cell factories for tissue processing and generation of
cells for therapeutic purposes. The adipose-derived stem cell
field is at a turning point as it moves from basic science to
clinical application. Solid research in the basic science and
biology behind stem cells has been performed, but a gap still
exists between basic knowledge and clinical application. In
the past decade, several skills have been obtained regarding
isolation, morphological characteristics, molecular biology,
and the differentiation potentiality of in vitro stem cells.
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